The company (abbreviation: Kangxino Biotech, stock code 6185.HK,688185.SH) was registered in Tianjin Binhai New Area in 2009. It is a national high-tech enterprise founded by a team of executives of multinational pharmaceutical companies returning to China. With the mission of providing solutions to prevent infectious diseases and infectious diseases around the world, Kangcino Biotech specializes in the R&D, production and commercialization of high-quality vaccines for human use, and is a leading high-tech biological products enterprise in China. In March 2019, Cansino Biotech was listed on H shares on the main board of the Hong Kong Stock Exchange; on August 13, 2020, Kangcino Biotech officially landed on the Science and Technology Innovation Board, becoming the first “A+H” vaccine stock since the opening of the Science and Technology Innovation Board. The company is a company dedicated to the development, production and commercialization of innovative vaccines that meet Chinese and international standards. The company is gradually developing 17 innovative vaccine products for 12 indications to prevent Ebola virus disease, meningitis, COVID-19, tetanus pertussis, pneumonia, tuberculosis, and shingles. Corporate honors: National High-tech Enterprise, Tianjin Key Laboratory for Respiratory Bacterial Recombination and Combined Vaccine Enterprises, Nankai University Talent Training Cooperative Development Base, Tianjin Model Group, etc.
No Data